News and Trends 3 Mar 2023Debiopharm adds to oncology pipeline Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting… March 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email